Summary
BeiGene, Ltd. (ONC) presented a strong growth trajectory in its March 2, 2020, 10-K filing, driven by significant advancements in its product pipeline and strategic collaborations. The company is focused on developing and commercializing innovative cancer therapeutics, with a growing commercial presence in China and the United States. Key internal developments include the U.S. FDA accelerated approval and launch of BRUKINSA™ (zanubrutinib) for mantle cell lymphoma and the NMPA approval in China for tislelizumab for classical Hodgkin's lymphoma. These approvals, along with a robust pipeline of internally developed and in-licensed assets, position BeiGene for substantial market penetration. The company also highlighted its strategic collaboration with Amgen, which includes the commercialization of Amgen's oncology products in China and joint global development of Amgen's pipeline assets, alongside a significant equity investment by Amgen. BeiGene's operational strategy emphasizes building strong clinical development and commercial capabilities, particularly leveraging the evolving regulatory landscape in China. Despite significant research and development expenses and net losses, the company's substantial cash reserves and strong partnerships indicate a forward-looking approach to growth and innovation in the oncology space.
Financial Highlights
57 data points| Revenue | $428.21M |
| Cost of Revenue | $71.19M |
| Gross Profit | $357.02M |
| R&D Expenses | $927.34M |
| SG&A Expenses | $388.25M |
| Operating Expenses | $1.39B |
| Operating Income | -$959.89M |
| Interest Expense | $15.15M |
| Net Income | -$950.58M |
| EPS (Basic) | $-1.22 |
| EPS (Diluted) | $-1.22 |
| Shares Outstanding (Basic) | 780.70M |
| Shares Outstanding (Diluted) | 780.70M |
Key Highlights
- 1Secured U.S. FDA accelerated approval and launched BRUKINSA™ (zanubrutinib) for mantle cell lymphoma.
- 2Received NMPA approval in China for tislelizumab for classical Hodgkin’s Lymphoma (cHL).
- 3Entered into a significant strategic oncology collaboration with Amgen, including a $2.8 billion equity investment, enhancing global development and China commercialization capabilities.
- 4Expanded its commercial portfolio with in-licensed drugs from BMS (ABRAXANE, REVLIMID, VIDAZA) and upcoming launches of Amgen and EUSA Pharma products in China.
- 5Reported substantial increases in total revenues driven by product sales and collaboration revenue, despite significant ongoing investment in research and development.
- 6Maintains a robust pipeline with multiple internally discovered drug candidates in various stages of clinical development.
- 7Invested heavily in building internal manufacturing capabilities with state-of-the-art facilities in China to support global product launches.